Nanoparticle, Raman-based Fiber-optic Glucose Sensor

纳米颗粒、基于拉曼的光纤血糖传感器

• 批准号: 6777226
• 负责人: JOSEPH T WALSH
• 金额: $ 13.8万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-01 至 2005-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6777226
• 关键词: Raman spectrometry; artificial endocrine pancreas; bioengineering /biomedical engineering; biomedical equipment development; biosensor device; clinical biomedical equipment; diabetes mellitus; fiber optics; laboratory rat; male; nanomedicine; nanotechnology

DESCRIPTION (provided by applicant): NIH estimates approximately 17 million Americans have diabetes mellitus, with approximately 1/10 of these being type 1 and the remaining being classified as type 2, gestational, and other. The disease can be characterized by long-term complications involving eyes, kidneys, nerves, and blood vessels are common but are limited with tight glycemic control characterized by near-normal glycosylated hemoglobin. The goal of the proposed research is to prove that a sensor based on Surface Enhanced Raman Spectroscopy (SERS) can be used to measure glucose levels in vivo with sufficient accuracy for feedback control of insulin delivery. We propose to develop the fiber-optic-based sensor, test the sensor in vitro and in vivo, and acquire sufficient data in vivo to specify the system requirements for use in human trials. Much of the previous work in the field of glucose sensing has focused on minimally invasive means of measuring blood glucose levels; such systems will allow patients to avoid repeated painful finger-pricks but glucose control would still be based on patient-dependant feedback control. Implanted electrochemical sensors have been FDA-cleared since mid-1999, but they must be physician implanted and their use in real-time glucose control has been limited. Our preliminary SERS work, based on noble metal nanoparticles has shown the potential accuracy and precision of a SERS sensor for glucose. We propose that an advanced version of this SERS sensor could be passed through the skin into the subcutaneous space, in a manner similar to the placement of insulin-pump-based catheters, and replaced every 3 days, which is the current norm for insulin-pump catheters. The nanoparticle-based SERS system provides a direct measure of glucose concentration, can monitor glucose levels continuously, is not based upon consumables (e.g. enzymes or substrates), and like all Raman-based analysis is specific to glucose and relatively insensitive to confounding analytes. We envision using these sensors to close the feedback loop by using the continuous measurement of glucose to control insulin levels, thus freeing the patient of repeated measurements, carbohydrate-counting, and insulin-dosing problems.

描述（由申请人提供）： NIH 估计大约有 1700 万美国人患有糖尿病，其中大约 1/10 为 1 型，其余为 2 型、妊娠期糖尿病和其他糖尿病。该疾病的特点是涉及眼睛、肾脏、神经和血管的长期并发症很常见，但受到严格血糖控制的限制，其特征是糖化血红蛋白接近正常。拟议研究的目标是证明基于表面增强拉曼光谱（SERS）的传感器可用于测量体内葡萄糖水平，并具有足够的精度来反馈控制胰岛素输送。我们建议开发基于光纤的传感器，在体外和体内测试传感器，并获取足够的体内数据以确定用于人体试验的系统要求。 葡萄糖传感领域之前的大部分工作都集中在测量血糖水平的微创方法上。这种系统将使患者避免反复刺痛手指，但血糖控制仍将基于患者相关的反馈控制。植入式电化学传感器自 1999 年中期以来已获得 FDA 批准，但它们必须由医生植入，并且它们在实时血糖控制中的应用受到限制。我们基于贵金属纳米粒子的初步 SERS 工作表明了葡萄糖 SERS 传感器的潜在准确性和精确度。我们建议，这种 SERS 传感器的高级版本可以通过皮肤进入皮下空间，其方式类似于放置基于胰岛素泵的导管，并且每 3 天更换一次，这是胰岛素的当前标准。泵导管。基于纳米粒子的 SERS 系统提供了葡萄糖浓度的直接测量，可以连续监测葡萄糖水平，不基于消耗品（例如酶或底物），并且像所有基于拉曼的分析一样，只针对葡萄糖，并且对混杂分析物相对不敏感。我们设想使用这些传感器通过连续测量葡萄糖来控制胰岛素水平来闭合反馈回路，从而使患者摆脱重复测量、碳水化合物计数和胰岛素剂量问题。